SCHEMBL25751772

SCHEMBL25751772

CCn1cnc(-c2cc(C(=O)OC)ccc2OC)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
KMT2A Q03164 3/20 0.42
GLA P06280 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 2/20 0.41
MGLL Q99685 1/20 0.40
CTSA P10619 1/20 0.40
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39
ESR1 P03372 1/20 0.39
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
VDR P11473 1/20 0.39
RXRA P19793 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751034 0.83 KMT2A (0.50) MAPTKMT2AGLACYP2C9CTSA
SCHEMBL27199356 0.82 MAPT (0.41) MAPTKMT2AGLASMN1; SMN2CYP1A2
SCHEMBL27199517 0.80 MAPT (0.45) MAPTKMT2AGLACTSAMEN1
SCHEMBL30498109 0.80 MAPT (0.45) MAPTKMT2AGLACTSAMEN1
SCHEMBL30498274 0.78 CYP2D6 (0.48) MAPTKMT2AGLASMN1; SMN2KDM4E
SCHEMBL27199580 0.78 CYP2D6 (0.48) MAPTKMT2AGLASMN1; SMN2KDM4E
SCHEMBL31017456 0.77 CYP1A2 (0.43) KMT2ASMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL30498147 0.75 MAPT (0.45) MAPTKMT2AKDM4EMEN1RAB9A
SCHEMBL27199412 0.75 MAPT (0.45) MAPTKMT2AKDM4EMEN1RAB9A
SCHEMBL31017379 0.74 ALDH1A1 (0.39) MAPTKMT2ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885GLA 3386/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885GLA 3386/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885GLA 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.